ALKERMES (ALKS) is specialized in drug delivery that enhances therapeutic outcomes. Lead commercial product, Risperdal® Consta™ [(risperidone) long-acting injection], is the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and is marketed worldwide by Janssen-Cilag ("Janssen").

The company's lead proprietary product candidate, Vivitrex® [(naltrexone) long-acting injection], is a once-a-month injection for the treatment of alcohol dependence. Its pipeline of extended-release injectable products and pulmonary drug products is based on its proprietary technology and expertise. Five other products are in mid-phase clinical or preclinal development. Alkermes' product development strategy is twofold: partnering its proprietary technology systems and drug delivery expertise with several large pharmaceutical companies, and developing novel, proprietary drug candidates for its own account. www.alkermes.com

2008

07/24/08	Supplemental New Drug Application for RISPERDAL(R) CONSTA(R) Submitted to the FDA for the Treatment of Bipolar Disorder
07/14/08	Alkermes Presents Positive Preclinical Data on Naltrexone for Extended-Release Injectable Suspension at Annual Meeting of Controlled Release Society
07/01/08	Alkermes Presents Positive Data on Proprietary Molecules Targeting Opioid Receptors
06/26/08	Alkermes Initiates Phase 3 Clinical Study of VIVITROL(R) for the Treatment of Opioid Dependence
06/16/08	Alkermes Expands Common Stock Repurchase Program and Raises Fiscal Year 2009 Financial Expectations
06/09/08	After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
06/07/08	Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
05/27/08	Alkermes' Corporate Presentation to be Webcast at the Friedman, Billings, Ramsey Spring Investor Conference
05/22/08	Alkermes Reports Financial Results for Fiscal 2008 and Provides Financial Expectations for Fiscal 2009
05/15/08	Alkermes to Host Conference Call to Discuss Fiscal Year 2008 Financial Results
05/08/08	Alkermes' Corporate Presentation to be Webcast at the Banc of America Securities Health Care Conference
05/06/08	Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
04/28/08	Alkermes' Corporate Presentation to Be Webcast at the Morgan Stanley Global Healthcare Unplugged Conference
04/14/08	Supplemental New Drug Application for RISPERDAL(R) CONSTA(R) Submitted to the FDA for the Treatment of Frequently Relapsing Bipolar Disorder
03/19/08	Alkermes Announces Restructuring
03/13/08	Alkermes' Corporate Presentation to Be Webcast at the Cowen and Company Health Care Conference
03/07/08	Alkermes Receives Notice from Eli Lilly Terminating Inhaled Insulin Program
03/07/08	Alkermes Provides Update on Inhaled Insulin Program
02/07/08	Alkermes Announces $60 Million Accelerated Share Repurchase Program
02/07/08	Alkermes Announces Third Quarter Fiscal 2008 Results
02/04/08	Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder
01/31/08	Alkermes to Host Conference Call to Discuss Financial Results for Third Quarter of Fiscal 2008
01/29/08	Alkermes' Corporate Presentation to be Webcast at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
01/07/08	Alkermes Announces Agreement for the Commercialization of VIVITROL in Russia/CIS
01/02/08	Alkermes' Corporate Presentation to be Webcast at JPMorgan Annual Healthcare Conference Certain statements set forth above may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and the company's business is subject to significant risk and uncertainties and there can be no assurance that its actual results will not differ materially from its expectations. These risks and uncertainties include, among others, decisions by the FDA relating to the recently submitted sNDAs for RISPERDAL CONSTA for the treatment of bipolar disorder and FRBD. For further information with respect to factors that could cause the company's actual results to differ materially from expectations, reference is made to the reports the Company filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. The forward-looking statements made in this release are made only as of the date hereof and the company disclaims any intention or responsibility for updating predictions or financial expectations contained in this release.

News

Stocks >> Stocks Details